References
- Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa G D. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2004; 60: 302–308
- Holgate S T, Chuchalin A G, Hebert J, Lotvall J, Persson G B, Chung K F, Bousquet J, Kerstjens H A, Thirwell J, Cioppa G D. Omalizumab 011 International Study Group:Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34: 632–638
- Walker S, Monteil M, Phelan K, Lasserson T J, Walters E H. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006, Apr; (2); CD003559
- Owen C E. Immunoglobulin E:Role in asthma and allergic disease:Lessons from the clinic. Pharmacol Therapeutics 2007; 113: 121–133
- Hochhaus G, Brookman L, Fox H, Johanson C, Matthews J, Ren S, Deniz Y. Pharmacodynamics of Omalizumab:implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19: 491–498
- Lane J E, Cheyney J M, Lane T N, Kent D E, Cohen D J. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006; 54: 68–72
- van d er, Ent C K, Hoekstra H, Rijkers G T. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007; 62: 276–277
- Buhl R, Berdel D, Criee C P, Gillissen A, Kardos P, Kroegel C, Leupold W, Lindemann H, Magnussen H, Nowak D, Pfeiffer-Kascha D, Rabe K, Rolke M, Schultze-Werninghaus G, Sitter H, Ukena D, Vogelmeier C, Welte T, Wettengel R, Worth H. Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. Pneumologie 2006; 60: 139–183
- Petersen A B, Gudmann P, Milvang-Gronager P, Morkeberg R, Bogestrand S, Linneberg A, Johansen N. Performance evaluation of a specific IgE assay developed for the ADVIA Centaur® immunoassay system. Clinical Biochemistry 2004; 37: 882–892
- Busse W, Corren J, Lanier B Q, McAlary M, Fowler-Taylor A, Cioppa G D, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184–190
- Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254–261
- Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalisations in patients with allergic asthma. J Allergy Clin Immunol 2003; 111: 87–90
- Vignola A M, Humbert M, Bousquet J, Boulet L P, Hedgecock S, Blogg M, Fox H, Surrey K. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis (SOLAR). Allergy 2004; 59: 709–717
- Hamilton R G, Marcotte G V, Saini S S. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving Omalizumab (Xolair) therapy. J Immunol Methods 2005; 303: 81–91
- Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh K M, Ramos S, Canonica G W, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment, INNOVATE). Allergy 2005; 60: 309–316
- Ruffin C G, Busch B E. Omalizumab:a recombinant humanized anti-IgE antibody for allergic asthma. Am J Health Syst Pharm 2004; 61: 1449–1455
- Casale T B, Bernstein I L, Busse W W, LaForce C F, Tinkelman D G, Stoltz R R, Dockhorn R J, Reimann J, Su J Q, Fick R B, Adelman D C. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100: 110–121
- Bousquet J, Rabe K, Humbert M, Chung K F, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, Holgate S. Predicting and evaluating response omalizumab on patients with severe allergic asthma. Respir Med 2007; 101: 1483–1492, Epub 2007 Mar 6
- Hanf G, Brachmann I, Kleine-Tebbe J, Seybold J, Kunkel G, Suttorp N, Noga O. Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. Allergy 2007; 61: 1141–1144